Sunrun Inc.
—- Market cap
- —
- Debt
- —
- Cash
- −$823.38M
Complete market value, debt and cash evidence is required for enterprise value.
Compare price, profitability, solvency, and SEC-reported financials side by side—before deciding which assumptions deserve a closer look.
Decision snapshot: RUN stock price vs WAT: inconclusive Relative valuation is incomplete for this pair. Review the available filing metrics before drawing a conclusion.
Quick read
Each company valued on the other's multiple, then compared with the market price.
Implied fair value · at WAT's multiple
Needs WAT P/E.
Implied fair value · at RUN's multiple
Needs RUN P/E.
Price unavailable
Metric by metric
Where each company leads, and how wide the gap is.
Growth edge
Reported gross margin
Operating income + D&A
Lower is better
Not comparable
Lower leverage
Statements
Annual statements in reported currencies, with calculations and source evidence.
Values retain reported currencies and share bases. Select a figure to inspect its period, calculation and filing inputs. Differences require compatible units and periods.
Explore enterprise value and market valuation multiples in the valuation sections.
Trendline
16 period-end years of reported revenue, earnings, and margins. Periods and currencies are shown with the data.
Price framework
USD market cap plus reported borrowing debt, less cash and equivalents. This EV proxy excludes investments, preferred stock and noncontrolling-interest adjustments.
Complete market value, debt and cash evidence is required for enterprise value.
Complete market value, debt and cash evidence is required for enterprise value.
Price framework
The same filing-backed model used on each company's valuation page, with company-specific inputs and calculated scenarios.
Sunrun Inc. · implied price per share
Five annual free-cash-flow observations are required for the filing-backed baseline.
Waters Corporation · implied price per share
Five annual free-cash-flow observations are required for the filing-backed baseline.
Balance sheet health
Inspect reported liquidity and leverage alongside historical financial-health checks.
Financial strength on a 0–9 scale.
Bankruptcy-risk signal from balance sheet and earnings power.
Not enough data to score either balance sheet.
Comparable set
Where the pair sits against the wider comparable set.
Keep comparing
Open adjacent comparisons from the same industry to pressure-test the read across multiple pairs.
SOLAREDGE TECHNOLOGIES, INC.
RUN vs SEDG
Enphase Energy, Inc.
RUN vs ENPH
FIRST SOLAR, INC.
RUN vs FSLR
Fluence Energy, Inc.
RUN vs FLNC
DANAHER CORP /DE/
RUN vs DHR
AGILENT TECHNOLOGIES, INC.
RUN vs A
BIO-RAD LABORATORIES, INC.
RUN vs BIO
THERMO FISHER SCIENTIFIC INC.
RUN vs TMO
BRUKER CORP
RUN vs BRKR
BIO-TECHNE Corp
RUN vs TECH
Cash excludes investments. EBITDA is an operating-income-plus-D&A proxy. Missing borrowing categories remain unavailable; select a value to inspect its inputs.
LLM-powered synthesis
An explanation of the financial evidence. Check its snapshot date against the figures above.
This explanation uses an earlier data snapshot or evidence version. Review its generation date and the current figures, or refresh after signing in.
If you believe RUN can convert its rapid revenue growth into sustained positive operating margins and reduce leverage, then the stock could warrant accumulation because the DCF and WAT-implied values sit far above the current price; however, based on today’s quality and balance-sheet data, the valuation gap looks more like compensation for risk than an obvious bargain.
RUN trades at 6.7x P/E and 0.9x P/S versus WAT at 34.2x P/E and 11.4x P/S, but RUN’s discount is paired with materially weaker profitability and leverage. The current price of $11.44 is only modestly above the historical band midpoint and far below both WAT-implied range and the DCF range, suggesting the market is already pricing in significant risk.
Supporting Metrics